Intra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up After Analyst Upgrade

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s stock price gapped up before the market opened on Tuesday after Needham & Company LLC raised their price target on the stock from $90.00 to $94.00. The stock had previously closed at $68.87, but opened at $76.07. Needham & Company LLC currently has a buy rating on the stock. Intra-Cellular Therapies shares last traded at $71.86, with a volume of 843,807 shares.

A number of other analysts also recently commented on the stock. TD Cowen increased their price objective on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Bank of America increased their price target on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. JPMorgan Chase & Co. boosted their price objective on Intra-Cellular Therapies from $75.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $120.00 target price on shares of Intra-Cellular Therapies in a research note on Friday, June 14th. Finally, The Goldman Sachs Group boosted their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research report on Wednesday, April 17th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $91.83.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Farallon Capital Management LLC purchased a new position in Intra-Cellular Therapies in the 1st quarter valued at approximately $15,985,000. Tidal Investments LLC increased its holdings in Intra-Cellular Therapies by 13.9% during the 1st quarter. Tidal Investments LLC now owns 3,698 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 450 shares during the period. Avoro Capital Advisors LLC raised its position in Intra-Cellular Therapies by 9.7% in the 1st quarter. Avoro Capital Advisors LLC now owns 2,475,000 shares of the biopharmaceutical company’s stock valued at $171,270,000 after purchasing an additional 219,445 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in Intra-Cellular Therapies in the first quarter worth approximately $3,460,000. Finally, EntryPoint Capital LLC grew its stake in shares of Intra-Cellular Therapies by 138.7% during the first quarter. EntryPoint Capital LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 1,259 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 9.6 %

The company has a 50-day moving average price of $69.17 and a 200-day moving average price of $68.50.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The company had revenue of $144.90 million during the quarter, compared to the consensus estimate of $141.41 million. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. Intra-Cellular Therapies’s revenue for the quarter was up 52.0% on a year-over-year basis. Equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.51 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.